Generic availability, a drug-class comparison, and a discovery origin story

psychopharmref.com · 2026-07-30

Pfizer is currently reporting a shortage of diazepam injection due to manufacturing delays, a situation that remains active as of June 2026 and is reflected in real-time tracking by the American Society of Health-System Pharmacists (ASHP, 2026-06-30). Diazepam injection is used in inpatient and emergency psychiatric settings primarily for acute agitation, alcohol withdrawal seizure prophylaxis and treatment, and status epilepticus — contexts in which oral or rectal substitution is often clinically inadequate. The shortage affects Pfizer's supply specifically; ASHP notes that other manufacturers retain available inventory, meaning the shortage is manufacturer-specific rather than a market-wide stockout (ASHP, 2026-06-30). Clinicians and pharmacists should confirm current stock levels with their institution's pharmacy, as regional distribution gaps can persist even when national supply exists on paper.

The broader landscape reinforces why this matters. ASHP reports 227 active national drug shortages as of June 2026, with 16 percent involving controlled substances — a category that includes benzodiazepines (ASHP, 2026-07-28). Diazepam injection is a Schedule IV controlled substance, and its supply constraints sit within a pattern of intermittent CNS agent shortages that have persisted across multiple quarters.

For clinicians managing patients who would ordinarily receive parenteral diazepam, the alternatives depend on the clinical indication. In alcohol withdrawal requiring intravenous benzodiazepine therapy, lorazepam injection (available from multiple manufacturers and not currently listed in shortage) is a pharmacologically reasonable substitution; it lacks active metabolites, which simplifies dosing in hepatically compromised patients, though its shorter duration of action may require more frequent reassessment using a structured withdrawal scale such as the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised — a 10-item clinician-rated instrument widely used to guide benzodiazepine dosing decisions in alcohol withdrawal). For procedural sedation or acute seizure management, midazolam injection is another available parenteral option, though its ultra-short duration limits utility in prolonged withdrawal management. Intramuscular formulations of lorazepam absorb reliably, which is clinically relevant when intravenous access is delayed.

Any substitution should be documented at the prescribing level with explicit rationale, and institutions should review their withdrawal management protocols now rather than at the point of stockout. Clinicians wanting current manufacturer-level detail and resolution timelines can consult the FDA Drug Shortages Database and ASHP's current shortages list directly. For a deeper look at a related topic, see the PsychoPharmRef post linked below.

Further reading on PsychoPharmRef: EKG Findings in Psychiatric Practice: QT Prolongation, Drug Interactions, and Clinical Monitoring, Understanding Medication Access: From Production to Patient

New on the psychpharmref.com website:

psychopharmref.com · 2026-07-30

Aripiprazole and quetiapine extended-release are among the most frequently used adjunctive atypical antipsychotics in patients with MDD who have not responded adequately to first-line antidepressant therapy. A 2026 JAMA Psychiatry systematic review and network meta-analysis of 22 randomized controlled trials involving 10,962 participants — the most comprehensive head-to-head comparison published to date — provides a useful framework for weighing their relative efficacy and tolerability profiles in this population (JAMA Psychiatry Network Meta-Analysis, 2026).

Regarding efficacy, both agents demonstrated statistically significant advantages in remission and response over placebo as adjunctive treatments. The 2026 network meta-analysis reported that aripiprazole and quetiapine XR produced broadly comparable effect sizes for remission, with neither clearly dominating the other on that primary outcome. Where the two diverge meaningfully is on the tolerability axis. Quetiapine XR carries a substantially heavier metabolic burden — weight gain, dyslipidemia, and sedation are common, the last of which may be dose-limiting in many outpatients. Aripiprazole's partial dopamine agonist mechanism confers a more favorable metabolic profile and less sedation, though akathisia occurs in a clinically relevant proportion of patients and can itself drive discontinuation (JAMA Psychiatry Network Meta-Analysis, 2026).

Context from STAR*D (Sequenced Treatment Alternatives to Relieve Depression, the landmark NIMH-funded multi-step trial that shaped augmentation practice across the 2000s) reinforced that sequential augmentation strategies yield diminishing remission rates at each step. A RIAT (Restoring Invisible and Abandoned Trials — a methodology for reanalyzing clinical trials with full fidelity to the original protocol) reanalysis of STAR*D patient-level data, published as a preprint in October 2025, applied strict adherence to the original remission criteria and found step-2 augmentation remission rates somewhat lower than those in the original published report, underscoring the need for realistic expectations when moving to adjunctive strategies (medRxiv RIAT Reanalysis, 2025). A 2026 Mayo Clinic Depression Center panel article similarly emphasized that augmentation choice should be individualized, with tolerability and patient-specific risk factors weighted alongside efficacy data (Mayo Clinic Depression Center Panel, 2026).

Pharmacokinetically, quetiapine XR requires titration — typically starting at 50 mg nightly and advancing to 150–300 mg — and its active metabolite norquetiapine contributes both antidepressant and sedative effects through norepinephrine reuptake inhibition and H1 antagonism, respectively. Aripiprazole is typically initiated at 2–5 mg daily and titrated to 5–15 mg; its long half-life of approximately 75 hours (94 hours for its active metabolite dehydro-aripiprazole) supports once-daily dosing and a forgiving missed-dose pharmacology. Both are CYP2D6 and CYP3A4 substrates, making drug-interaction review essential when co-prescribing with SSRIs such as fluoxetine or paroxetine, which significantly inhibit CYP2D6 and can raise aripiprazole levels.

In practice, aripiprazole tends to be preferred in younger patients, those with metabolic risk factors, or individuals where sedation would impair function. Quetiapine XR may be favored where sleep disruption or anxiety comorbidity is prominent and where the sedating profile serves a secondary clinical goal. In geriatric patients, both agents carry FDA black-box warnings for increased mortality in dementia-related psychosis; quetiapine's orthostatic and sedative effects warrant particular caution in this population. Cost and formulary access remain relevant: both are generically available, but prior authorization requirements vary across payers.

For a deeper look at dopaminergic pharmacology in treatment-resistant contexts, see the PsychoPharmRef post linked below.

Further reading on PsychoPharmRef: Serotonin Syndrome vs NMS: Diagnosis, Differentiation, and Emergency Management, Clozapine: The Gold Standard for Treatment-Resistant Schizophrenia

psychopharmref.com · 2026-07-30

The story of chlorpromazine begins not in a psychiatric ward but in an operating theater in Paris, where a French naval surgeon named Henri Laborit was searching for a better way to prevent surgical shock. In December 1951, the chemist Paul Charpentier at Rhône-Poulenc (a French pharmaceutical firm that would later merge into Sanofi) synthesized compound 4560 RP — chlorpromazine — as part of a program exploring phenothiazine derivatives originally intended as antihistamines (Fifty years chlorpromazine: a historical perspective, 2007). Laborit, who had been experimenting with "lytic cocktails" to calm patients before surgery, noticed that chlorpromazine produced a distinctive state: patients became tranquil and indifferent to their surroundings without losing consciousness. He described this as an "artificial hibernation" and, crucially, urged his psychiatric colleagues to investigate the compound's potential for mental illness (Chlorpromazine, the first antipsychotic medication: history, controversy and legacy, 2016).

That encouragement reached Jean Delay and Pierre Deniker at the Hôpital Sainte-Anne (a historic Parisian psychiatric hospital that served as France's leading center for clinical psychiatry in the mid-twentieth century). In 1952, Delay and Deniker administered chlorpromazine to acutely psychotic patients and observed rapid, dramatic improvements in agitation, hallucinations, and delusions — effects that could not be explained by sedation alone. Their published case series, presented that same year, constituted the first systematic clinical evidence that a chemical compound could specifically target psychotic symptoms (Fifty years chlorpromazine: a historical perspective, 2007). The drug reached the North American market as Thorazine in 1954 after Smith, Kline & French licensed it from Rhône-Poulenc, and within two years it was being used in psychiatric hospitals across the United States and Europe.

Chlorpromazine's impact on institutional psychiatry was swift and measurable: state hospital populations, which had been climbing for decades, began a sustained decline (History of Psychopharmacology, 2019). Yet the drug's trajectory also illustrates the field's persistent tension between commercial ambition and scientific understanding. The dopamine-blocking mechanism of action was not elucidated until the 1960s and 1970s, meaning the drug was prescribed for years without a coherent pharmacological rationale. Generic chlorpromazine entered the market in the 1970s, and its clinical use gradually narrowed as newer antipsychotics with different side-effect profiles emerged. The lesson chlorpromazine offers is both humbling and instructive: the founding molecule of modern psychopharmacology was born from antihistamine chemistry, recognized by a surgeon rather than a psychiatrist, and deployed clinically a full generation before its mechanism was understood (A Brief History of Psychiatric Drug Development, 2020).

For a deeper look at antipsychotic pharmacology and clinical considerations, see the PsychoPharmRef post linked below.

Further reading on PsychoPharmRef: Antipsychotic Medications: A Comprehensive Clinical Review, Neutropenia and Psychiatric Medications

Found this useful? Reply to this email with your thoughts, or become a paid supporter to keep this going.